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Introduction
The aim of the review was to identify and assess modelling approaches used to date in cost-
effectiveness analyses of interventions for heart failure (HF), updating a previous review published by 
Goehler et al. in 20111.
Methods
A systematic search was carried out of the literature with studies published up to September 2016 across 
Medline, Embase, Cochrane Library, EconLit and CINAHL databases. We included studies that reported a 
model-based evaluation, including both costs and health impacts, of an HF intervention where they were 
available in full text in English. Studies reporting only cost-effectiveness analyses alongside a clinical trial 
were excluded. 
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Figure 2 Flow chart summarising the systematic review process
a)
b)
Figure 3  Summary of the characteristics of identified models including a) type of intervention being assessed and 
b) type of model used
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New York Heart Association (NYHA) functional classification of heart failure
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Class I
Mild
No fatigue with 
ordinary physical 
activity
Class II
Mild
Ordinary physical 
activity results in 
fatigue, palpitations, 
shortness of breath
Class III
Moderate
Less than ordinary 
physical activity 
results in fatigue, 
palpitations, 
shortness of breath
Class IV
Severe
Any physical activity 
results in fatigue, 
palpitations, 
shortness of breath
Figure 1 Illustration of the NYHA functional classification of heart failure
Results
Figure 2 illustrates the screening process, which identified 56 papers describing 54 different modelling 
studies. The studies assessed a range of interventions including surgical (e.g. implanted devices), medical 
(pharmaceutical), service-level (e.g. multi-disciplinary teams), screening or monitoring (e.g. for biomarkers) 
or disease management programmes as summarised in Figure 3 (a). Markov cohort modelling was the most 
commonly used methodology as shown in Figure 3 (b). There was a range of complexity levels within the 
Markov modelling studies. Some studies used very simple two-state models with cohorts partitioned into 
either ‘alive’ or ‘dead’ states, whereas others allowed for disease progression. Disease progression was 
generally modelled with reference to New York Heart Association (NYHA) functional classifications (see 
Figure 1). In additional to functional classification, several models included additional health states for 
hospitalisation events, since acute episodes in HF have both an immediate effect on patient health-related 
quality of life (HRQoL) as well as an impact on the future risk of both death and additional hospitalisation 
events.
Conclusions
The simple Markov cohort approach appears appropriate for estimating cost effectiveness in most cases. 
Efforts to model the natural history of HF progression have to date centred on the use of NYHA functional 
classification, which is based on a subjective rating rather than a physiological measure and has been shown 
to have high interoperator variability in assignment2. Despite this, there is evidence that HRQoL does vary 
by NYHA class3 and therefore this measure may be considered a useful proxy for progression in terms of 
capturing HRQoL effects.
Future modelling may further consider the modelling of natural history using health states informed by 
health outcome measures commonly used in HF.
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